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Summary. Campath-1H, an anti-CD52 monoclonal anti-
body, is therapeutically active in lymphoproliferative and
autoimmune diseases. After Campath-1H therapy, lympho-
cytes with a paroxysmal nocturnal haemoglobinuria (PNH)
phenotype have been reported to emerge. We characterized
a PNH-like lymphocyte population emerging after Campath-
1H therapy, in a patient with fludarabine refractory B-cell
chronic lymphocytic leukaemia (B-CLL). We demonstrated a
reduction in PIG-A mRNA levels compared with controls,
and of all cytokines tested [interleukin (IL)-4, IL-13, IL-2,
interferon(IFN)-g, IL-6, IL-10, and tumour necrosis factor
(TNF)-a], except transforming growth factor (TGF)-b. Given
the inhibitory activity of TGF-b, its elevated levels may
contribute to the selective pressure of Campath-1H, leading
to the emergence of PNH-like lymphocytes.
Keywords: Campath-1H, CLL, cytokines, PIG-A, PNH-like
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Campath-1H, a humanized monoclonal antibody against
CD52, is increasingly used in the treatment of lymphoid
malignancies, autoimmune disease and bone marrow
transplantation. After Campath-1H treatment, the emer-
gence of lymphocytes deficient in glycosylphosphatidy-
linositol (GPI)-anchored proteins has been described
(Hertenstein et al, 1995; Brett et al, 1996; Taylor et al,
1997). The phenotype of these CD52-negative B and T cells
closely resembles that of lymphocytes from paroxysmal
nocturnal haemoglobinuria (PNH) patients, in which the
first step of the GPI-biosynthetic pathway is blocked (Rowan
et al, 1998). The molecular involvement by mutation of the
PIG-A gene in these PNH-like lymphocytes is controversial
(Hertenstein et al, 1995; Taylor et al, 1997) and has been
described in one B cell chronic lymphocytic leukaemia (B-
CLL) patient who developed PNH-like T lymphocytes after
treatment with Campath-1H (Rawstron et al, 1999).
We characterized the PNH-like lymphocyte population
that emerged in a patient affected by fludarabine refractory
B-CLL after treatment with Campath-1H, using molecular
analysis and determination of cytokine production.
The patient, a 57-year-old man, was diagnosed with B-
CLL (SmIgM, Gl) Binet stage C in 1991. He was initially
treated with alkylating agents, followed by a-interferon
(IFN) maintenance, obtaining a partial remission. A
progression of disease occurred in 1997 and fludarabine
treatment was started with no response. In October 1998,
Campath-1H treatment (30 mg every other day for
12 weeks) was started for disease progression. Post-treat-
ment evaluation revealed a complete remission in the
peripheral blood and bone marrow (CD5/CD19 double-
positive cells , 3% using flow cytometry). After Campath-
1H treatment, the great majority of the patient’s lymphoid
cells were represented by PNH-like T-lymphocytes, with
loss of CD52 (Fig 1A,B), 55, and 59 expression (data not
shown). Notwithstanding the lymphocyte PNH phenotype,
the study of the entire codifying region and flanking
intronic sequences of the PIG-A gene, using single-stranded
conformation polymorphism (SSCP) analysis, showed no
abnormal electrophoretic patterns suggestive of gene muta-
tion. To test the hypothesis that the loss of GPI-anchored
proteins may be the result of reduced levels of PIG-A mRNA,
we assessed the PIG-A mRNA levels using quantitative-
competitive reverse transcription-polymerase chain reaction
(RT-PCR). Interestingly, the expression of PIG-A mRNA was
reduced compared with normal controls (5  1032104
molecules in four consecutive samples during Campath-1H
treatment, versus 105 molecules in three normal controls
(see Fig 1C). These findings may suggest a possible role for
defective PIG-A mRNA production in the genesis of PNH-like
lymphocytes, even in the absence of detectable PIG-A gene
mutations (Rawstron et al, 1999). Regarding cytokine
production (Table I), we found that all cytokines, except
transforming growth factor (TGF)-b, were reduced com-
pared with CLL control-patients and to a greater extent than
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Fig 1. (A and B) Flow cytometric analysis of the patient’s lymphocytes after Campath-1H treatment. Mononuclear cells were separated from
peripheral blood using a Ficoll-Hypaque density gradient. The cells were analysed by two-colour immunofluorescence staining with the
indicated fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-labelled monoclonal antibodies. The analysis was performed using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). A portion of each sample was incubated with the appropriate isotype control-
antibodies to establish the background level of non-specific staining, and positivity was defined as staining greater than non-specific
background staining. (A) left, gated event; right, 1·84% of B lymphocytes co-expressed CD52 antigen. (B) left, gated events; right, 2·47% of T-
lymphocytes co-expressed CD52 antigen. Before Campath-1H treatment, . 90% of the patient’s T-lymphocytes and . 90% of the B-
lymphocytes co-expressed CD52 antigen (data not shown). (C) Evaluation of the expression of PIG-A gene in the patient and in normal controls
by quantitative-competitive PCR. The competitor was obtained using a 36-bp PCR internal deletion of the PIG-A cDNA fragment to be
quantified. In the first PCR round forward 1 (5 0-CTGTACTAAGAGCAGCACTG-3 0) and reverse (5 0-CTGTCATGCAGCTGGTATCT-3 0) primers were
used, generating a fragment of 274 bp; in the second PCR round, the 274 bp fragment was amplified in the presence of reverse primer and
forward 2 primer (5 0-CTGTACTAAGAGCAGCACTGGATCCTACTGACTTCACTCC-3 0), a hybrid represented by forward 1 sequence fused to a
cDNA PIG-A sequence 36 bp downstream. Therefore, a PCR fragment of 238 bp derived from PIG-A cDNA, delimited by forward 1 and reverse
sequences was generated. Total RNA (1 mg) was reverse transcribed to cDNA and for quantitative-competitive PCR, 100 ng of product were
amplified in the presence of scalar amounts of competitor molecules using forward 1 and reverse primers. PCR conditions were as follows: hot
start, 5 min at 958C; 35 cycles at 958C for 50 s, 558C for 50 s and 728C for 60 s, the same used to generate the competitor. Equivalence
(indicated by an arrow) was 5  103 molecules/100 ng of total RNA in the patient, and 105 molecules/100 ng of total RNA in controls. M,
molecular markers (Amplisize Molecular Ruler 50–2000 bp, Biorad, Hercules, California, USA).
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normal controls. Interleukin (IL)-4 and IL-13 production
was very low and IL-2, IFN-g, IL-6, IL-10 and tumour
necrosis factor (TNF)-a were, on average, 20–30% of
normal controls and 50% of CLL patients. Interestingly,
TGF-b production was disproportionately high compared
with the other cytokines; furthermore, it was comparable to
normal controls and threefold greater than the production
occurring in CLL patients.
Several abnormalities of cytokine production have been
described in CLL regarding both the B and T cell
compartment, including reduced IL-4, IFN-g (Hill et al,
1999) and IL-6 (Hulkkonen et al, 1998), which have been
related to the cellular and humoral immune defects of the
disease. However, little is known about cytokine production
by PNH lymphocytes, except for reduced IL-2 release in
patients with aplastic anaemia who progressed to clinical
PNH (Nissen et al, 1999). Compared with the CLL group, we
found increased production of TGF-b, a well-known
inhibitory cytokine. Excessive production of TGF-b by bone
marrow stromal cells has been hypothesized to be respon-
sible for the inhibitory activity on haematopoietic precursors
in CLL (Lagneaux et al, 1993). Given the inhibitory activity
of TGF-b, our results may suggest that elevated levels of this
cytokine could contribute to alterations of the micro-
environment and synergize with the selective pressure of
Campath-1H, leading to expansion of pre-existing PNH-like
lymphocytes (Rawstron et al, 1999).
The study of larger series, and in particular of classical
PNH lymphocytes, will be necessary to demonstrate if this
cytokine production pattern is characteristic of the PNH-like
lymphocytes emerging after Campath-1H treatment.
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Table I. Cytokine production by mitogen-stimulated blood cul-
tures.
Patient Normal controls CLL
IL-2 35 ^ 11 237 ^ 17 117 ^ 28
IFN-g 926 ^ 265 5147 ^ 304 3234 ^ 519
IL-4 1·9 ^ 0·5 21·5 ^ 1·9 9·7 ^ 2·9
IL-6 540 1 235 2245 ^ 120 939 ^ 161
IL-10 115 ^ 37 435 ^ 44 218 ^ 43
IL-13 1·2 ^ 0·5 133 ^ 14 129 ^ 24
TNF-a 53 ^ 11 147 ^ 18 96 ^ 22
TGF-b 1649 ^ 317 1394 ^ 78 630 ^ 134
Blood cultures were stimulated with phytohaemagglutinin (PHA,
1 mg/ml) and supernatants collected after 48 h. Cytokine measure-
ment was performed using the commercially available enzyme-
linked immunosorbent assay (ELISA) kits. Values are expressed as
pg  1029/cell, and were obtained by dividing the cytokine
concentration in supernatants by the number of peripheral blood
mononuclear cells present in culture. Values for normal controls
and CLL patients are the mean ^ SD of 46 and 47 subjects
respectively. Values for the patient under study are the mean ^ SD
of four consecutive determinations performed between March and
December 1999.
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